Bausch Health Companies Inc. (TSE:BHC – Get Free Report)’s stock price traded up 8.4% on Thursday following a stronger than expected earnings report. The company traded as high as C$12.37 and last traded at C$12.33. 36,968 shares were traded during mid-day trading, a decline of 90% from the average session volume of 370,617 shares. The stock had previously closed at C$11.37.
The company reported C$1.53 EPS for the quarter, topping the consensus estimate of C$1.43 by C$0.10. The firm had revenue of C$3.42 billion during the quarter, compared to analyst estimates of C$3.36 billion. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on BHC. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Raymond James raised shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 10th.
Insiders Place Their Bets
In related news, Senior Officer Seana Lynne Carson sold 13,370 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total value of C$112,087.40. Insiders own 11.28% of the company’s stock.
Bausch Health Companies Stock Performance
The stock has a market capitalization of C$4.55 billion, a PE ratio of -7.05, a P/E/G ratio of 0.21 and a beta of 0.77. The firm’s 50 day moving average is C$9.82 and its two-hundred day moving average is C$9.87. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19.
About Bausch Health Companies
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
- Five stocks we like better than Bausch Health Companies
- How to Calculate Inflation Rate
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Earnings Per Share Calculator: How to Calculate EPS
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- What is a support level?
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
